Clinical outcomes of the study cohort
| Suspected CAP cohort (n=111) | With probable Aspergillus infection (n=26; 23.4%) | Without probable Aspergillus infection (n=85; 76.6%) | P value | |
| Mortality | ||||
| Mortality (28 days) | 34 (30.6) | 12 (46.2) | 22 (25.9) | 0.05 |
| Mortality (60 days) | 1 (0.9) | 0 | 1 (1.2) | 1.000 |
| Mortality (90 days) | 4 (3.6) | 0 | 4 (4.7) | 0.571 |
| Hospital mortality | 18 (16.2) | 8 (30.8) | 10 (11.8) | 0.021 |
| ICU mortality (76) | 18/76 (23.7) | 8/19 (42.1) | 10/57 (17.5) | 0.029 |
| Prognosis | ||||
| Improvement in clinical status, median (IQR), days | 14 (7–19) | 13.5 (0–23) | 14 (7–18) | 0.848 |
| Ventilator-free days within 28 days, median (IQR) | 26 (18–28) | 24 (12–28) | 26 (19–28) | 0.290 |
| Supplemental oxygen independence days within 28 days, median (IQR), days | 14 (8–21) | 12.5 (4.5–23.5) | 15 (10–21) | 0.457 |
| Duration of ICU stay, median (IQR), days | 7 (0–14) | 12 (0–16) | 7 (0–12) | 0.087 |
| Duration of hospital stay, median (IQR), days | 16 (12–22) | 18.5 (13–27) | 16 (10–21) | 0.058 |
| Treatment | ||||
| Multiple antifungal drugs* | 11 (10.8) | 6 (23.1) | 5 (5.9) | 0.010 |
| Main antifungal therapy† | ||||
| Voriconazole | 21 (18.9) | 14 (53.9) | 7 (8.2) | 0.000 |
| Amphotericin B | 3 (2.7) | 1 (3.8) | 2 (2.4) | 1.000 |
| Caspofungin | 18 (16.2) | 5 (19.2) | 13 (15.3) | 0.634 |
Data are n (%) or median (IQR), unless otherwise specified. When no denominator is specified, the denominator is the number of participants in the corresponding cell in the first row. Parenthetical values in the stub column represent the number of patients for whom data were available.
*Multiple antifungal drugs: used in combination or consecutively.
†Main antifungal therapy: first antifungal drug administered for ≥5 consecutive days following invasive pulmonary aspergillosis diagnosis.
CAP, community-acquired pneumonia; ICU, intensive care unit.